Monday, March 17, 2025 | 08:10 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Merck says it has first effective antiviral pill against Covid-19 pandemic

Drug cuts hospitalisation, deaths by 50%, shows an analysis of a late-stage trial

Rob Davis, Merck CEO
Premium

The company is halting the study and will seek an emergency-use authorization from the US Food and Drug Administration as quickly as possible, Chief Executive Officer Rob Davis said

Emma Court | Bloomberg
Merck & Co’s Covid-19 antiviral pill molnupiravir reduced the risk of hospitalisation or death by 50 per cent in an interim analysis of a late-stage trial, findings that could give doctors another potent virus-fighting tool.
 
The company is halting the study and will seek an emergency-use authorization from the US Food and Drug Administration as quickly as possible, Chief Executive Officer Rob Davis said in an interview. Merck also plans to submit applications to regulators in other countries.  “We couldn’t be more thrilled with the results,” Davis said. “You don’t have to go to the hospital, you don’t have

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in